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Tumor development is a complex process that relies on interaction and communication between a number of cellular
compartments. Much of the mass of a solid tumor is comprised of the stroma which is richly invested with extracellular matrix.
Withinthismatrixareahostofmatricellularproteinsthatregulatetheexpressionandfunctionofamyriadofproteinsthatregulate
tumorigenic processes. One of the processes that is vital to tumor growth and progression is angiogenesis, or the formation of new
blood vessels from preexisting vasculature. Within the extracellular matrix are structural proteins, a host of proteases, and resident
pro- and antiangiogenic factors that control tumor angiogenesis in a tightly regulated fashion. This paper discusses the role that
the extracellular matrix and ECM proteins play in the regulation of tumor angiogenesis.
1.Introduction
Conventional cancer treatments typically target the epithe-
lial component of carcinomas, which represent a varying
proportion of tumors. More recently, a paradigm shift
has occurred wherein epithelial cells are being evaluated
as a functional and complex system along with stromal
components [1]. These stromal cells are typically recruited
by tumors and include ﬁbroblasts, endothelial cells, smooth
muscle cells and immune cells. Recruitment of stromal
factors not only provide a structural extracellular matrix
(ECM) scaﬀold that provides structural support, but also
generates pleiotrophic eﬀects which contribute to tumori-
genecity, thus a tumor phenotype is not only characteristic
of the transformed cells, but also the ECM and stroma
surrounding the cells. Stromal recruitment and alterations
in the ECM result in complex communication networks
between cancerous cells which may provide ideal targets for
future therapies [2, 3].
The extracellular matrix provides structural support
for cells within a tumor providing anchorage for cells
and separating tissues, however it also acts homoestatically
to mediate communication between cells and contributes
survival and diﬀerentiation signals. The ECM contains a
basement membrane that separates cells from the interstitial
matrix. At this junction, molecular components of the
ECM can be found including proteoglycan, nonproteoglycan
polysaccharides, and various ﬁbrous proteins. The carbohy-
drate polymers and proteins are organized in such a way that
an interlocking meshwork exists and is the basic framework
for the ECM.
It is known that the ECM has structural components
that neoplastic cells can exploit to create a protumor
environment. Studies have found that injecting tumorigenic
cells into the site of origin (orthotopically) results in a
more replicable onset and progression in a variety of tumors
in diﬀerent mouse models [2, 3]. Others have reported
the necessity of the native microenvironment in order to
accurately mimic the metastatic disease [4]. Our laboratory
has investigated this relationship between tumor cells and
the host stroma using an orthotopic model of epithelial
ovarian cancer. In this model, transformed epithelial cells are
injecteddirectlyundertheovarianbursawheretheycanthen
colonize and grow. In this model, the ovarian epithelial cells
interact with the ovarian stroma and result in the formation
of primary serous adenocarcinoma, numerous secondary2 Journal of Oncology
peritoneal lesions, and the formation of abdominal ascites
which closely replicate the features of human epithelial
ovarian cancer. The importance of the interaction between
the epithelial cells and the tumor stroma is apparent as this
interaction causes a reprogramming of the epithelial cells,
increasing their metastatic potential; when the tumorigenic
epithelial cells were injected intraperitoneally instead of
orthotopically, the lack of stromal interaction resulted in
the formation of small spheroids within the abdomen, as
opposed to well-diﬀerentiated peritoneal lesions generated
with the orthotopic model [5].
2. Tumor Angiogenesis
Investigation into the roles of the tumor stroma have
established that the ECM plays an important role in tumor
vascularization [6]. Cancer cells which have acquired several
mutations have the ability to be: self-suﬃcient in growth
signalling via activation of oncogenes or loss of tumor sup-
pressorgenes,insensitivetoantigrowthsignals,unresponsive
to apoptotic events, capable of limitless replication, and
tumorigenic. Although all of these neoplastic properties are
necessary for tumor development, they are not suﬃcient to
become clinically relevant cancers unless the tumor is able to
recruit its own blood supply [8]. In most tumors, new blood
vessels are formed through a process called angiogenesis, in
which new blood vessels form from preexisting vasculature
[7, 8]. Tumors require the ability to establish an angiogenic
phenotype, which occurs via the angiogenic switch [9]. The
angiogenic switch is regulated by a balance between pro and
antiangiogenic factors and when the balance is disrupted,
pathological conditions such as cancer can result [10].
Proangiogenic factors such as growth factors and
cytokines stimulate the formation of tumor blood vessels.
Two of the most critical and widely studied proangiogenic
factors include vascular endothelial growth factor (VEGF)
[11] and basic ﬁbroblast growth factor (bFGF) [12, 13]
(reviewed in [14]). These factors stimulate endothelial cells
to produce and export various proteolytic enzymes that
enable cell invasion and metastasis by degradation of the
extracellular and intracellular proteins of the ECM, allowing
endothelial cells to proliferate, and migrate into surrounding
tissues, [15]. Under normal physiologic conditions these
proteolytic enzymes are involved in wound healing and
matrix remodelling. Overexpression of VEGF [16, 17]a n d
bFGF [18–21] have been shown to promote tumorigenic
properties by triggering angiogenesis. Therefore, inhibition
of proangiogenic factors or upregulation of antiangiogenic
factors could lead to an eﬀective therapeutic approach.
Ultimately, the angiogenic shift must favour expression of
antiangiogenic factors in order for vessel regression to occur.
3. Regulation of Angiogenesis by the ECM
The angiogenic process is complex and involves endothelial
cell proliferation and migration, degradation of the blood
vessel basement membrane and associated extracellular
matrix. Following endothelial cell proliferation and early
tube formation, newly formed vessels diﬀerentiate into
arterioles and venules, necessary to provide blood supply
to tumors [8, 22]. Remodelling of the ECM is an integral
component of the angiogenic process. A variety of mecha-
nisms have been documented about how the ECM plays a
pivotal role in regulating angiogenesis (reviewed by [23]).
The ECM is composed of a network of ﬁbrous proteins
and glycosaminoglycans (GAGs). GAGs are carbohydrate
polymers that form proteoglycans that are involved in
both keeping the EMC and surrounding cells hydrated
and trapping and storing growth factors. Therefore, GAG
molecules may employ a variety of regulatory eﬀects on
the accessibility of angiogenic factors [24, 25]. Release
of proteolytic enzymes leading to the degradation of the
ECM results in the release of ECM-bound growth factors
such as VEGF ([26]; reviewed by [25]). Heparan sulfate
glycosaminoglycans (HSGAGs) are a diverse family of GAGs
that include the syndecans, glypicans, perlecans and agrins.
Members of this group of proteins play a key role in the
modulation of angiogenesis. HSGAGs that are present on the
surface of endothelial cells have the ability to either inhibit or
promote neovascularization by mediating signalling through
VEGF receptors [27] or bFGF [28, 29]. As well, HSGAGs
can also act as a binding site for antiangiogenic factor
endostatin[30].Fibrousproteinsincludecollagenandelastin
both of which are well characterized structural proteins
components of the skin, connective tissue and blood vessel
walls. Collagen involvement in angiogenesis has recently
received a great deal of attention. Metabolic inhibition of
the synthesis of type I and IV inhibits capillary formation
on the CAM [31]. Data has shown that components of
the ECM can have both pro and antiangiogenic eﬀects.
Proteases involved in degrading the ECM and often activated
duringremodellingcanpromoteangiogenesisbystimulating
migration of endothelial cells or by releasing proangiogenic
growth factors [32, 33]. Angiogenesis can also be inhibited
when antiangiogenic compounds are secreted from the
fragments formed during proteolytic cleavage of matrix
molecules [34, 35]. This paper will focus on proteases and
matrix-related molecules that have been found to inﬂuence
tumor angiogenesis.
4. ECMProteinsInvolvedinRemodeling and
Tumor Angiogenesis
Major ECM proteins that promote angiogenesis include
collagen, laminin and ﬁbronectin. Collagen IV and laminin
are predominate proteins of the basal lamina, a 50nm wide
ECM that provides structural support for endothelial cells
and creates a separation from the adjacent perivascular cells.
The majority of ECM proteins mediate angiogenesis through
arginine-glycine-aspartic acid (RGD) motifs which bind to
integrins that mediate outside in signalling. Endothelial cells
in a resting quiescent state exhibit the lowest mitotic index
of cells within the body [36]. Induction of angiogenesis
and remodelling of the ECM is characterized by increased
permeabilityandcytoskeletalandcell-to-cellcontactchanges
which results in newly formed focal contacts mediatedJournal of Oncology 3
primarily by integrins. Fibronectin is produced by both
activated endothelial and smooth muscle cells, levels are aug-
mented during angiogenesis by delivery of ﬁbronectin from
circulation by increased vascular permeability. Fibronectin
contains the arginine-glycine-aspartic acid (RGD) protein
motifs that bind to the integrin α5β1. This integrin receptor
is markedly up regulated during angiogenesis and is over-
expressed in endothelial cells in tumors. Mice genetically
engineered to lack the α5 integrin subunit die during
embryogenesis due to fail of the yolk sac vasculature to form
properly [37–39]. The collagen integrin receptors (α1β1a n d
α2β1) also play a positive role for angiogenesis. Use of a
potent and speciﬁc α1β1 inhibitor Obtustatin, is able to
inhibit angiogenesis in the chick chorioallantoic membrane
(CAM)assayandintheLewislungsyngeneicmodel[40,41].
Finally laminin peptides derived from the α1 chain mediate
angiogenesis in vitro [41–43]. Receptors involved in laminins
proangiogenic properties have not been fully elucidated,
α6β1 receptor may play important role in tube formation
[44].
Proteolytic activity of the ECM facilitates degradation
of the basement membrane, matrix remodelling, and cell
migration and invasion, all of which are essential for
angiogenesis. In order for angiogenesis to occur, activation
of proteases is essential. However, aberrantly excessive degra-
dation of the ECM does not permit developing vessels [32].
Therefore,inasimilarfashiontotheregulationofangiogenic
processes by angiogenesis by pro and antiangiogenic factors,
activation of proteolytic enzymes of the ECM is also tightly
regulated. There are two main classes of enzymes that have
been studied for their abilities to degrade and remodel
the ECM: the plasminogen activator (PA)/plasmin system
and matrix metalloproteinases (MMPs), which have been
reviewed for their roles in angiogenesis [45]. To date, a
number of MMPs have been shown to degrade the vascular
basement membrane and matrix in order to permit vascular
sprouting. The activity of these proteases is regulated by
endogenous tissue inhibitors of metalloproteinases (TIMPs)
which generally have antiangiogenic properties.
MMPs are a group of zinc-dependent proteases that are
involved in the degradation and remodelling of the ECM in
order for processes such as angiogenesis to occur. The MMP
family consists of over 20 proteases and many of them have
been implicated in tumorigenesis [32]. Those that have been
reported to have proangiogenic actions are described below.
By degrading the matrix, MMPs not only provide physical
space within the matrix for migration, but also provide
proliferation and diﬀerentiation signals to endothelial cells
by releasing cryptic sites on ECM proteins and soluble
growth factors. The involvement of MMPs in angiogenesis
has been supported through the use of knockout mice.
Studies involving knockout mice of the gelatinase type
MMPs (MMP-2 and MMP-9) have shown tumor angiogen-
esis [46]. Researchers have subsequently shown that MMP-
2 promotes an angiogenic phenotype, while suppression of
the protease inhibited angiogenesis [47]. MMPs cleave ECM
bound growth factors including proangiogenic factors [48].
Various MMPs have been found to cleave heparin bound
growth factors such as VEGF and bFGF, releasing soluble
forms which then exert proangiogenic actions and stimulate
the formation of new blood vessels [49]. In particular, it
was reported that MMP-9 stimulates the production of the
proangiogenic growth factor VEGF [50, 51]. Other members
of the MMP family have also been shown to enhance the
eﬀectiveness of proangiogenic growth factors. Membrane
bound MMPs also mediate proangiogenic eﬀects. Corneal
pocket implantation assays revealed that MT1-MMP can
potentiate the neovascularization eﬀects of basic ﬁbroblast
growth factor (bFGF) [52]. When cells that do not normally
express MT1-MMP were transfected with the matrix pro-
tease, angiogenesis was stimulated and in vivo, neovascular-
izationwasassociatedwithanincreaseinexpressionofVEGF
[53].InaxenograftmodelofGlioma,cellsthatoverexpressed
MT1-MMPwerecapableofremodellingamatrixinvitroand
had increased levels of angiogenesis in vivo. Consistent with
other studies, these changes in angiogenesis were correlated
with an increase in VEGF [54]. This is maintained during
situations in which MMPs are decreased, ultimately resulting
in a reduction in the levels of proangiogenic growth factors
[55]. Stromal recruitment of ﬁbroblasts and immune cells
such as macrophages can also modulate MMP remodelling
of the stroma altering the signalling that ultimately results
in increases and decreases of angiogenesis. Recently loss
of PTEN signalling in stromal ﬁbroblasts results in the
induction of ECM remodelling by the increase of the tran-
scriptional factor Ets2 which is an upstream target of MMP9
[56]. Protease mediated cleavage of the ECM also results
in the release of cryptic antiangiogenic factors. Cleavage of
basement membrane proteins, collagen XVIII and the α1, α2
andα3chainsofcollagenIVreleasetheangiogenicinhibitors
endostatin, arrestin, canstatin and tumstatin, respectively
[57]. Endostatin once release from mature collagen XVIII
binds to cell surface proteoglycans, VEGFR-2 and the α5β1
integrin to inhibit angiogenesis in vitro and in vivo [57].
Due to the longer half-life on these endogenous inhibitors of
angiogenesis, it has been hypothesized that they accumulate
in the serum of patients with larger primary neoplasia and
inhibit angiogenesis at distal sites and limit the growth
of metastatic foci until resection of the primary lesion
[58].
As mentioned, remodelling of the ECM is a tightly
regulated process. The inhibitory inﬂuence that the TIMPs
have on MMP expression and function therefore is an
important regulator of matrix degradation. Overexpression
of TIMP-1 has shown to suppress tumorigenesis, in part
due to its eﬀects on the tumor vasculature. Immunostaining
revealedthatmicethatoverexpressedtheendogenousTIMP-
1hadsigniﬁcantlyreducedtumorvesseldensitycomparedto
controls (REF). In vitro treatment with TIMP-1 showed that
tube formation was altered despite no signiﬁcant changes
in endothelial cell proliferation. Decreased expression of
MMP-2 and MMP-9 in the tumors of TIMP-1 transgenic
mice but not in the in vitro experiments, suggest that
inhibition of the matrix degradation is not a direct eﬀect
on MMPs, but may require the presence of a reactive stroma
[59]. In vitro, TIMP-2 decreases proliferation of endothelial
cells and inhibits angiogenesis in vivo [60, 61]. Other in
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of tumors overexpressing TIMP-2 reported a decrease in
microvessel density compared to controls [62]. Although the
mechanisms by which protease inhibitors such as TIMP-2
inhibit angiogenesis are not well understood, it is thought
to be the result of a decrease in proangiogenic factors such
as VEGF [63] and bFGF [64]. TIMP-3 has also shown
to decrease angiogenesis, particularly through inhibition of
endothelial tube formation and disaggregation of endothe-
lial cells [65–67]. Support for TIMP-3 as a therapeutic
comes from studies involving animals that were deﬁcient
in the protease inhibitor exhibited an increased angiogenic
phenotype [68]. TIMPs have been reported to not only
inﬂuence the vasculature, but in some cases, exert their
antiangiogenic properties through an MMP-independent
mechanism [69–71]. In 2003, Fern´ andez et al. characterized
the antiangiogenic domains of TIMP-2, a protease inhibitor
which decreases endothelial cell proliferation. In this study,
they found that both terminal domains of the protein were
capable of inhibiting angiogenesis. It was also noted that
only the domain which does not function with MMPs was
able to inhibit mitogen-driven angiogenesis. This can be
interpreted that therapeutics that solely target MMPs to
inhibit angiogenesis might not be as eﬀective as TIMPs
[72].
Another group of ECM proteins which have recently
been studied for their role in tumor angiogenesis are a
disintegrin and metalloproteinases (ADAMs) and a disin-
tegrin and metalloproteinase with thrombospondin motifs
(ADAMTs). Besides the addition of thrombospondin (TSP)
motifs on these proteases, the ADAMs are associated with
the membrane while the ADAMTs are secreted [73]. These
proteins belong to a similar family as MMPs and many of
them have been found to regulate angiogenesis directly or
through expression of MMPs. ADAM-17 has been reported
to play a role in angiogenesis as was evident from in vitro
experiments on endothelial cells. Inhibiting ADAM-17 not
only altered morphology of the endothelial cells but it also
decreased proliferation, leaving apoptosis unchanged. In
terms of elucidating how ADAM-17 inﬂuences angiogenesis,
this was determined to be the result of MMP-2 activation via
VEGF. The involvement of ADAM-17 was conﬁrmed when
endothelial cells lacking the protein did not have an increase
in MMP-2 following VEGF treatment [74]. Evaluation of the
ﬁrst thrombospondin repeat (TSR1) in ADAMTS5 revealed
inhibition of endothelial tube formation and proliferation
[75]. Unlike ADAM-17, ADAMTS5 induced endothelial cell
death even in the presence of VEGF, a potent proangiogenic
and growth promoting factor. ADAMTS1 and ADAMTS8
have also been identiﬁed for containing the antiangio-
genic domain (TSR1) of thrombospondin. Both these pro-
teins inhibited endothelial cell proliferation and suppressed
growth factor induced vascularization of various assays [76].
Luque et al., elaborated on the function of ADAMTS1 to
inhibit angiogenesis by decreasing VEGF. They found that
ADAMTS1 binds VEGF which ultimately interferes with its
ability to interact with its receptor VEGFR2, as was evident
from lack of phosphorylation [77].
The ECM protein SPARC is a multifunctional matricel-
lular glycoprotein that has been evaluated in various cancers
but its role as either a tumor promoter or inhibitor has been
controversial (reviewed by [78]). However, with respect to
its eﬀect on blood vessels, SPARC has been reported to be
an antiangiogenic factor [79]. In this study, over-expression
of SPARC in a glioma cell line resulted in a decrease in
vascularity of xenograft tumors. It was also determined that
the antiangiogenic eﬀects of SPARC were associated with
reduced tumor levels of VEGF [80]. SPARC also directly
inhibitsendothelialcellbindingtotheextracellularmatrixby
modulating extracellular calcium levels, eﬀectively inhibiting
blood vessel migration through the tumor stroma [81].
Other studies have shown that SPARC interferes with the
growth promoting eﬀects of VEGF on endothelial cells [82],
and promotes the assembly of tightly organized stroma that
doesnotpermitbloodvesselformationortumorprogression
[81].
Lastly is a group of ECM proteins classiﬁed as endoge-
nous inhibitors of angiogenesis which include various
antiangiogenic peptides, hormone metabolites and mod-
ulators of apoptosis [83]. Therapeutic drugs have been
developed based on matrix derived and nonmatrix-derived
endogenous angiogenic inhibitors [83, 84]. These inhibitors
can be classiﬁed based on whether they have solely angio-
genic actions or whether they have functions in addition to
angiogenic actions [84]. Of these, thrombospondin-1 was
the ﬁrst protein recognized as an endogenous inhibitor of
angiogenesis [85] and has since become a popular target for
the treatment of various cancers. The role of TSP-1 as an
antiangiogenic protein will be extensively reviewed.
Another class of proteins which have recently gained
recognition for their potential role in tumor angiogenesis
are the bone morphogenic proteins (BMPs). BMPs belong
to the transforming growth factor beta (TGFb) superfamily
of proteins and to date, more than 20 members have been
identiﬁed [86]. An angiogenic role of the BMPs has been
suggested due to a number of BMP mutations found in
various vascular diseases and abnormal angiogenesis that
occurs when BMP signalling is disrupted (reviewed by [87]).
One of the mechanisms by which the BMPs have been
reported to inﬂuence angiogenesis is by stimulating the
secretion of proangiogenic growth factors such as VEGF
[88]. BMP expression is associated with promoting tube
formation and endothelial cell migration, whereas these
activities are inhibited when BMP function is impaired [89].
Although BMPs are thought to stimulate angiogenesis, there
have also been reports that demonstrate an antiangiogenic
role [90, 91].
A s i d ef r o mad i r e c tr o l eo nb l o o dv e s s e lf o r m a t i o n ,
recent studies have implicated interactions between BMPs
and proteins of the ECM which can ultimately aﬀect
tumor growth and development. ECM proteins have been
reported to interfere with BMP signalling by altering the
bioavailability of TGFb (reviewed by [92]). BMPs are also
thought to play a critical role in metastatic processes. In a
model of prostate cancer, BMP-7 was shown to be highly
expressed in bone and soft tissue metastases compared to
the primary tumor and subcutaneous tumors formed from
prostate adenocarcinoma cells overexpressing BMP-7 had a
signiﬁcantly reduced tumor volume compared to those withJournal of Oncology 5
normal expression [93]. Similar results were reported in a
model of lung carcinoma [94] and these results illustrate
the relevance of the tissue microenvironment when studying
howBMPsaﬀecttumorgrowth.Itisthoughtthattumorcells
secrete BMPs which creates an environment that promotes
tumor cell growth and metastasis [95]. Studies have shown
that BMPs can contribute to decreased expression of various
MMPs [96–98]. A reduction in MMP expression would
permit metastatic cells to colonize and propagate in the
tissue. The role of BMPs in primary and secondary tumor
formation is not completely clear, however. Some evidence
points to the need for BMP inhibition before metastatic
spread can occur and it may be the case that the eﬀects
of members of the BMP family may be context-speciﬁc.
In an ovarian cancer model, it was shown that overex-
pression of the BMP receptor, ALK3 decreases adhesion of
epithelial ovarian cancer cells in vitro reduces formation of
intraperitoneal tumors and ascites ﬂuid in vivo [99]. Further
understanding of the role which BMPs play in the ECM
and with tumor angiogenesis will beneﬁt therapeutic studies
which target angiogenesis, tumour growth, and metastatic
spread of disease.
5.TSP FamilyofProteins
Thrombospondin was originally identiﬁed as thrombin-
sensitive protein by Baenziger et al., in the early 1970s. It
was later realized that the protein was a subunit of a larger
protein released from α granules of platelets in response
to activation by thrombin. The native protein was oﬃcially
named thrombospondin (TSP) [100, 101]. TSPs belong to
a family of multifunctional glycoproteins that have a high
aﬃnity for matrix molecules, plasma proteins, ions, and
various cell surfaces. They are capable of binding to heparin
[102–104], ﬁbronectin [105, 106], ﬁbrinogen [106–108],
plasminogen [109], histidine-rich glycoprotein [110], type
IV collagen [111], and calcium [112, 113]. (For an extensive
list of macromolecules that interacts with TSP see [114]. TSP
is also capable of associating with various cell types and their
corresponding extracellular matrices [115–119]. Combined,
these diverse interactions allow TSP to be involved in cell-to-
cell and cell-to-matrix communications (reviewed by [120]).
TSP is a 450kDA protein which is composed of three
150kDA disulﬁde-linked polypeptide chains [101, 121–125].
Each subunit of the trimer consists of multiple domains:
an N-terminal globular domain, a region homologous to
procollagen, three types of repeated sequence motifs (type
1, type 2, and type 3 repeats) and a C-terminal globular
domain [126]. There are ﬁve family members, TSP-1, -2, -
3, -4 and -5 [127–129]. The TSP family can be divided into
two subgroups on the basis of their oligomerization and
molecular architecture. TSP-1 and -2 are trimers that have
the same set of structural domains and belong to subgroup
A. They are members of the thrombospondin type-1 repeat
(TSR) supergene family whereas the remaining members of
the family lack the TSR and the procollagen domain, are
pentamers and are part of subgroup B [130].
6. Thrombospondin-1 (TSP-1) and
Tumor Angiogenesis
Thrombospondin-1(TSP-1)wastheﬁrstoftheﬁvemembers
to be identiﬁed as a major component of blood platelets.
Since its discovery, TSP-1 has been implicated in the
regulation of cell growth and proliferation [131, 132],
cell motility [85, 133, 134], cytoskeletal organization [135,
136], inﬂammatory responses [137, 138], development and
diﬀerentiation of various cell types [139], regulation of
angiogenesisduringwoundhealing[140],andtumorigenesis
[141]( r e v i e w e db y[ 114]).
Due to the complex structure of TSP-1, there are
multiple receptor binding domains located throughout the
peptide that are capable of various functions [126]. These
receptors include, low density lipoprotein receptor-related
protein (LRP), proteoglycans and sulfatides, CD36, inte-
grins, integrin-associated protein (IAP), and an unidentiﬁed
receptor located in the C-terminus [142]. Many membrane
proteins can also act as receptors for TSP-1 and activate
downstream signalling pathways [143].
Many human tumor cell lines express relatively low levels
of TSP-1 compared to normal or benign lines. It has also
been observed that cell lines with low metastatic potential
express higher levels of TSP-1 compared to metastatic lines
[144, 145]. This has further been validated in experiments
where TSP-1 transfection into human cancer cell lines
inhibitedprimarytumorformation[145,146]anddecreased
metastasisinvivo[145].Theseresultsproposeaninversecor-
relationbetweenTSP-1expressionandtumoraggressiveness,
whereby malignant progression is associated with reduced
levels of TSP-1 in certain cancers.
Overexpression of TSP-1 in cancer cell lines has been
showntosuppresstumorformationbytargetingthevascula-
ture [145–150]. Studies involving introduction of TSP-1 into
cell lines derived from gliobastoma multiforme induced the
angiogenic switch to an antiangiogenic phenotype. Angio-
genesis was measured by in vitro endothelial cell migration
and in vivo corneal neovascularization assays [148]. Other
in vivo studies have manipulated TSP-1 via transfection
into human cancer cells lines and subsequent injection
into nude mice. Angiogenesis is typically assessed based
on microvessel density (MVD) which utilizes endothelial
cell-speciﬁc markers, such as cluster of diﬀerentiation 31
(CD31) in order to perform vessel staining and counts. A
decrease in MVD was observed in primary tumors that
formed from the TSP-1 transfectant cell lines [145]. TSP-1
overexpression experiments in a model of human squamous
cell carcinoma revealed consistent results in that tumor
growth, vessel number, and size were drastically decreased.
Histological examination demonstrated that tumors derived
from TSP-1 stable transfected cells exhibited extensive areas
of tumor cell necrosis which might have been due to
the antiangiogenic eﬀects of TSP-1 on tumor vasculature
[149].
Clinicalstudiesofpatientswithbladder,papillarythyroid
and epithelial ovarian cancer have investigated levels of
TSP-1 and correlated it with angiogenesis. This relationship
was established based on a signiﬁcant association between6 Journal of Oncology
TSP-1 expression and MVD count. Tumors from patients
that expressed high levels of TSP-1 had low MVD counts
and were therefore more likely to exhibit a decrease in
angiogenesis compared to control tissue. The inverse has
also been documented; a decrease in TSP-1 expression was
accompanied with high MVD counts which may contribute
to an angiogenic phenotype [151–155].
Most studies have attempted to relate vascularity with
expression of TSP-1 by probing tumor tissue with endothe-
lial cell speciﬁc markers. Few studies have evaluated the
expression of TSP-1 in hypo- compared to hypervascular
carcinomas. There are however various human carcinomas
with a varying degree of vascularization and have been
used to determine how diminished vascularity relates to
expression of TSP-1. It was found that a hypovascularized
human carcinoma had increased levels of TSP-1 [156]. These
results defend the inverse relationship that exists between the
degree of vascularization and TSP-1 expression. They also
support TSP-1 as an antiangiogenic protein that regulates
tumorigenesis.
TSP-1 expression has also been a predictor of tumor
recurrence and overall survival. In clinical studies of patients
with invasive bladder cancer and papillary thyroid carci-
noma, low TSP-1 expression, as determined by immunohis-
tochemistry, was associated with an increased probability of
disease recurrence and decreased overall survival [151, 154].
Clinical studies of invasive epithelial and cervical cancer have
revealed that TSP-1 expression is a valuable prognostic factor
[155, 157]. In another study of invasive epithelial ovarian
cancer, the majority of cases expressed high levels of TSP-1
which was associated with a higher survival rate compared
to cases where tumors expressed lower levels of TSP-1 [152].
T h e5 - y e a rs u r v i v a lr a t eo fo r a ls q u a m o u sc e l lc a r c i n o m a
patients has also been shown to be signiﬁcantly higher in
tumors that express high levels of TSP-1 [153]. Based on this
evidence, it is likely that TSP-1 possesses a tumor inhibitory
function in some cancers and it may be a useful tool to assess
prognosis.
7. AntiangiogenicCompounds and
Vessel Normalization
The concept of antiangiogenic therapy for the treatment of
various cancers was postulated in 1971 by Judah Folkman.
It was hypothesized that solid tumor growth depends on
angiogenesis in order to grow beyond 1-2mm3. There-
fore, it was thought that angiogenic inhibitors might be
a potential therapeutic target; by blocking angiogenesis,
tumor dormancy could be initiated [7, 158]. In 1996,
Teicher proposed that antiangiogenic therapy would be most
eﬀective if used in combination with chemotherapy. The
rationale was that the combinatorial eﬀects would diminish
the tumor cells as well as the endothelial cells associated
with the tumor [159]. A hallmark of tumor angiogenesis
is that blood vessels are formed so rapidly that they often
become disorganized, torturous, and as a result have reduced
functional capacity [160]. These immature blood vessels
typically lack pericyte coverage, which may render them
more vulnerable to apoptotic signals [161]. In 2001, Jain
proposed the idea of tumor vasculature normalization as
the product of antiangiogenic treatment. Because of the
abnormal anatomy of tumor vessels perfusion is restricted,
resulting in areas of tumor hypoxia and necrosis. This
reduced blood ﬂow to the tumor impairs the delivery of
cytotoxic chemotherapeutic agents to the tumor interior,
inhibiting their eﬀectiveness, facilitating drug resistance
and tumor regrowth [162, 163]. Anti-angiogenic therapy
designed to target this abnormal, immature vasculature
could eﬀectively prune back vessels and increase blood
ﬂow, nutrient delivery, and waste removal. Combining vessel
normalization with chemotherapy would provide better
tissue perfusion of cytotoxic agents which induce apoptosis
of the tumor [164]. It has since been reported that agents
thatinhibitproangiogenicfactorsalterthetumorvasculature
and increase the delivery of chemotherapeutics when used
in combination [165]. Recent studies have utilized the
antiangiogenic peptide, TSP-1 for the treatment of various
cancers and have found that the compounds are capable
of normalizing tumor vasculature [166]. We have shown
that TSP-1 directly inhibits VEGF and reduces its availability
to ovarian cells [167]. In addition, we have shown that
treatment with the TSP-1 mimetic peptide ABT-510 signif-
icantly reduces ovarian tumor volume and vascularity [168].
Importantly, treatment with ABT-510 decreased overall
blood vessel density, but increased the proportion of mature,
pericyte-covered blood vessels and decreased tumor tissue
hypoxia.
If normalized vessels increase the uptake of chemothera-
peutic agents they may allow the drugs to be administered at
lower doses, which would minimize their many deleterious
side eﬀects. The beneﬁts are also supported by the fact that
if the tumor vasculature is normalized instead of completely
diminished, the tumor will not undergo hypoxia which is the
major activator of VEGF, a potent proangiogenic factor.
8. The Thrombospondins and
Other EMCProteins
The TSPs are also known to directly interact with other
ECM proteins in their regulation of tumor progression
and tumor angiogenesis. The Type 1 repeats of the TSP-1
and -2 genes inhibit MMP activity by preventing activation
of the MMP-2 and -9 zymogens [169]. Conversely, others
have reported that TSP-1 increases MMP-9 activity and
tumor cell invasion [170], suggesting that the interaction
between matricellular proteins may be context speciﬁc.
T S P - 1n u l lm i c eh a v er e d u c e de x p r e s s i o no fT G F β,l o w e r
collagen content and delayed wound closure [171]. We
also discovered that the ovaries of TSP-1 null mice were
hypervascularized,withincreasedexpressionofVEGF[5].In
vivo, TSP-1 binds to a number of matrix glycosaminoglycans
including heparan sulfate [172] chondroitin sulfate [173]
and binds to members of the syndecan family, versican,
and cerbroglycan [172–174] and these proteoglycans are
thought to be important mediators of TSP-1. Aside from
MMPs,TSP-1isalsoknowntoinhibittheactivityofplasmin,Journal of Oncology 7
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Figure 1: Summary of various extracellular matrix (ECM) proteins that are involved in tumour angiogenesis. Activation of tumor-derived
ECMproteinspermitscommunicationbetweenthetumoranditssurroundingmicroenvironment.Regulatingofangiogenesiscanbedirectly
through MMP activation and degradation of the ECM or through and indirect mechanism. This involves interactions between various ECM
proteins and pro or antiangiogenic growth factors in order to alter angiogenesis. Ultimately, expression of the proangiogenic growth factor
can inﬂuence the angiogenic phenotype and determine whether vascular sprouting occurs in order to provide the tumor with the necessary
nutrients to survive.
urokinase plasminogen activator, and elastin [175, 176],
which are all key components of the extracellular matrix and
are important in facilitating vessel invasion into the stroma.
AsidefromdirecteﬀectsonVEGFexpressionandendothelial
cells, TSP-1 appears to have potent antiangiogenic eﬀects
through its interaction with the extracellular matrix and on
a host of matricellular proteins.
9. Conclusion
Solid tumors exhibit signiﬁcant structural complexity and
progression of the disease is regulated by a host of diﬀerent
factors. This paper focused on the extracellular matrix
as a major contributor to tumorigenesis. Once cells have
undergone transformation and initiated the formation of a
tumor,theymustinteractwiththesurroundingenvironment
in order for tumor progression to occur [1]. This interaction
activates tumor-derived ECM proteins which can have
multiple eﬀects on the tumor stroma in order to promote
angiogenesis, a process which is essential for tumor growth
[6]. The involvement of the ECM in tumor angiogenesis
includes degradation of the basement membrane, matrix
remodelling, and cell migration and invasion [32]. In this
paper, we focused on ECM proteins that have both direct
and indirect roles on the regulation of angiogenesis. Many of
the ECM proteins appear to aﬀect angiogenesis by altering
expression of proangiogenic growth factors such as VEGF
and bFGF. Other ECM proteins such as SPARC, ADAMs,
and ADAMTs have also been investigated for their role
in angiogenesis. These proteins have been shown to have
direct antiangiogenic properties through their ability to
inhibit proangiogenic growth factors. Lastly, we reported on
the role of TSP-1 as it has been extensively studied with
respect to tumor angiogenesis. It has been well documented
that in vitro, TSP-1 decreases endothelial cell migration
and invasion and decreases tumor vasculature in vivo.T h e
involvement of ECM proteins in tumour angiogenesis is
s u m m a ri z e di nF i g u r e1. The potent antiangiogenic eﬀects of
TSP-1 have led to the development of mimetic peptides that
have shown signiﬁcant antiangiogenic and antitumorigenic
eﬀects in vivo. This review demonstrates the necessity for
investigation of the microenvironment of the tumor and also
supports the development of various therapeutics which can
target ECM proteins.8 Journal of Oncology
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